Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: Cytokines, antioxidants and psoriatic skin auto-fluorescence

Biomedicine and Pharmacotherapy

Volumn 66, Issue 4, 2012, Pages 293-299

  Portugal Cohen, Meital ^a,b   Horev, Liran ^c   Ruffer, Claas ^d   Schlippe, Gerrit ^d   Voss, Werner ^d   Ma'or, Ze'evi ^b   Oron, Miriam ^b   Soroka, Yoram ^e   Frušić Zlotkin, Marina ^e   Milner, Yoram ^e   Kohen, Ron ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b AHAVA Dead Sea Laboratories   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Dermatest Medical Research Company   (Germany)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Atopic dermatitis; Non invasive measurements; Psoriasis; Skin auto fluorescence; Skin wash sampling

Indexed keywords

COLLAGEN; ELASTIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; AUTOFLUORESCENCE; CONTROLLED STUDY; CROSS LINKING; FEMALE; FLUORESCENCE SPECTROSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN AUTOGRAFT;

ADOLESCENT; ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN; DERMATITIS, ATOPIC; ELASTIN; FEMALE; FLUORESCENCE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; MALE; MIDDLE AGED; PSORIASIS; SKIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84862501101     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.12.009     Document Type: Article

References (60)

1. Nomura I., Goleva E., Howell M.D., Hamid Q.A., Ong P.Y., Hall C.F., et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003, 171:3262-3269.
2. Williams H., Robertson C., Stewart A., Ait-Khaled N., Anabwani G., Anderson R., et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999, 103:125-138.
3. Nickoloff B.J. Creation of psoriatic plaques: the ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease viewpoint. J Cutan Pathol 2001, 28:57-64.
4. Leung D.Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000, 105:860-876.
5. Grice K., Sattar H., Baker H., Sharratt M. The relationship of transepidermal water loss to skin temperature in psoriasis and eczema. J Invest Dermatol 1975, 64:313-315.
6. Bos J.D., Kapsenberg M.L. The skin immune system: progress in cutaneous biology. Immunol Today 1993, 14:75-78.
7. Cooper K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol 1994, 102:128-137.
8. Bruch-Gerharz D., Fehsel K., Suschek C., Michel G., Ruzicka T., Kolb-Bachofen V. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996, 184:2007-2012.
9. Rowe A., Farrell A., Kazmi S.H., Bunker C.B. Expression of inducible nitric oxide synthase in dermal microvasculature in psoriasis. Lancet 1994, 344:1371.
10. Gaston L., Crombez J.C., Lassonde M., Bernier-Buzzanga J., Hodgins S. Psychological stress and psoriasis: experimental and prospective correlational studies. Acta Derm Venereol Suppl (Stockh) 1991, 156:37-43.
11. Harvima R.J., Viinamaki H., Harvima I.T., Naukkarinen A., Savolainen L., Aalto M.L., et al. Association of psychic stress with clinical severity and symptoms of psoriatic patients. Acta Derm Venereol 1996, 76:467-471.
12. Gladman D.D., Helliwell P., Mease P.J., Nash P., Ritchlin C., Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24-35.
13. Cohen A.D., Dreiher J., Shapiro Y., Vidavsky L., Vardy D.A., Davidovici B., et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008, 22:585-589.
14. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007, 56:629-634.
15. Gelfand J.M., Dommasch E.D., Shin D.B., Azfar R.S., Kurd S.K., Wang X., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009, 129:2411-2418.
16. Wadonda-Kabondo N., Sterne J.A., Golding J., Kennedy C.T., Archer C.B., Dunnill M.G. Association of parental eczema, hay fever, and asthma with atopic dermatitis in infancy: birth cohort study. Arch Dis Child 2004, 89:917-921.
17. Schmid-Ott G., Jaeger B., Adamek C., Koch H., Lamprecht F., Kapp A., et al. Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis. J Allergy Clin Immunol 2001, 107:171-177.
18. Portugal-Cohen M, Oron M, Ma'or Z, Boaz M, Shtendik L, Biro A, et al. Noninvasive skin measurements to monitor chronic renal failure pathogenesis. Biomed Pharmacother 2011.
19. Brancaleon L., Lin G., Kollias N. The in vivo fluorescence of tryptophan moieties in human skin increases with UV exposure and is a marker for epidermal proliferation. J Invest Dermatol 1999, 113:977-982.
20. Kollias N., Gillies R., Moran M., Kochevar I.E., Anderson R.R. Endogenous skin fluorescence includes bands that may serve as quantitative markers of aging and photoaging. J Invest Dermatol 1998, 111:776-780.
21. Leffell D.J., Stetz M.L., Milstone L.M., Deckelbaum L.I. In vivo fluorescence of human skin. A potential marker of photoaging. Arch Dermatol 1988, 124:1514-1518.
22. Na R., Stender I.M., Henriksen M., Wulf H.C. Autofluorescence of human skin is age-related after correction for skin pigmentation and redness. J Invest Dermatol 2001, 116:536-540.
23. Stamatas G.N., Estanislao R.B., Suero M., Rivera Z.S., Li J., Khaiat A., et al. Facial skin fluorescence as a marker of the skin's response to chronic environmental insults and its dependence on age. Br J Dermatol 2006, 154:125-132.
24. Tian W.D., Gillies R., Brancaleon L., Kollias N. Aging and effects of ultraviolet A exposure may be quantified by fluorescence excitation spectroscopy in vivo. J Invest Dermatol 2001, 116:840-845.
25. Kohen R., Gati I. Skin low molecular weight antioxidants and their role in aging and in oxidative stress. Toxicology 2000, 148:149-157.
26. Cao G., Verdon C.P., Wu A.H., Wang H., Prior R.L. Automated assay of oxygen radical absorbance capacity with the COBAS FARA II. Clin Chem 1995, 41:1738-1744.
27. Prior R.L., Hoang H., Gu L., Wu X., Bacchiocca M., Howard L., et al. Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (ORAC(FL))) of plasma and other biological and food samples. J Agric Food Chem 2003, 51:3273-3279.
28. Motchnik P.A., Frei B., Ames B.N. Measurement of antioxidants in human blood plasma. Methods Enzymol 1994, 234:269-279.
29. Gupta M.A., Gupta A.K., Schork N.J., Ellis C.N. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994, 56:36-40.
30. Trouba K.J., Hamadeh H.K., Amin R.P., Germolec D.R. Oxidative stress and its role in skin disease. Antioxid Redox Signal 2002, 4:665-673.
31. Bonifati C., Carducci M., Cordiali Fei P., Trento E., Sacerdoti G., Fazio M., et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994, 19:383-387.
32. Ettehadi P., Greaves M.W., Wallach D., Aderka D., Camp R.D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994, 96:146-151.
33. Olaniran A.K., Baker B.S., Paige D.G., Garioch J.J., Powles A.V., Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res 1996, 288:421-425.
34. Bonifati C., Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999, 38:241-251.
35. Nickoloff B.J., Karabin G.D., Barker J.N., Griffiths C.E., Sarma V., Mitra R.S., et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991, 138:129-140.
36. Mizutani H., Black R., Kupper T.S. Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 1991, 87:1066-1071.
37. Wakefield P.E., James W.D., Samlaska C.P., Meltzer M.S. Tumor necrosis factor. J Am Acad Dermatol 1991, 24:675-685.
38. Bonifati C., Carducci M., Mussi A., D'Auria L., Ameglio F. IL-1 alpha, IL-1 beta and psoriasis: conflicting results in the literature. Opposite behaviour of the two cytokines in lesional or non-lesional extracts of whole skin. J Biol Regul Homeost Agents 1997, 11:133-136.
39. Cooper K.D., Hammerberg C., Baadsgaard O., Elder J.T., Chan L.S., Sauder D.N., et al. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta. J Immunol 1990, 144:4593-4603.
40. Gruaz D., Didierjean L., Grassi J., Frobert Y., Dayer J.M., Saurat J.H. Interleukin 1 alpha and beta in psoriatic skin: enzymoimmunoassay, immunoblot studies and effect of systemic retinoids. Dermatologica 1989, 179:202-206.
41. Debets R., Hegmans J.P., Croughs P., Troost R.J., Prins J.B., Benner R., et al. The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis. J Immunol 1997, 158:2955-2963.
42. Debets R., Hegmans J.P., Troost R.J., Benner R., Prens E.P. Enhanced production of biologically active interleukin-1 alpha and interleukin-1 beta by psoriatic epidermal cells ex vivo: evidence of increased cytosolic interleukin-1 beta levels and facilitated interleukin-1 release. Eur J Immunol 1995, 25:1624-1630.
43. Kristensen M., Deleuran B., Eedy D.J., Feldmann M., Breathnach S.M., Brennan F.M. Distribution of interleukin 1 receptor antagonist protein (IRAP), interleukin 1 receptor, and interleukin 1 alpha in normal and psoriatic skin. Decreased expression of IRAP in psoriatic lesional epidermis. Br J Dermatol 1992, 127:305-311.
44. Romero L.I., Ikejima T., Pincus S.H. In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol 1989, 93:518-522.
45. Zhang B., Cao G.L., Cross A., Domachowske J.B., Rosen G.M. Differential antibacterial activity of nitric oxide from the immunological isozyme of nitric oxide synthase transduced into endothelial cells. Nitric Oxide 2002, 7:42-49.
46. Paquet P., Pierard G.E. Interleukin-6 and the skin. Int Arch Allergy Immunol 1996, 109:308-317.
47. Grossman R.M., Krueger J., Yourish D., Granelli-Piperno A., Murphy D.P., May L.T., et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A 1989, 86:6367-6371.
48. Portugal M., Barak V., Ginsburg I., Kohen R. Interplay among oxidants, antioxidants, and cytokines in skin disorders: present status and future considerations. Biomed Pharmacother 2007, 61:412-422.
49. Lontz W., Sirsjo A., Liu W., Lindberg M., Rollman O., Torma H. Increased mRNA expression of manganese superoxide dismutase in psoriasis skin lesions and in cultured human keratinocytes exposed to IL-1 beta and TNF-alpha. Free Radic Biol Med 1995, 18:349-355.
50. Therond P., Gerbaud P., Dimon S., Anderson W.B., Evain-Broin D., Raynaud F. Antioxidant enzymes in psoriatic fibroblasts and erythrocytes. J Invest Dermatol 1996, 106:1325-1328.
51. Severin E., Nave B., Stander M., Ott R., Traupe H. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999, 198:336-339.
52. Das U.N., Vijaykumar K., Madhavi N., Suryaprabha P., Sravankumar G., Ramesh G., et al. Psoriasis: current concepts and new approaches to therapy. Med Hypotheses 1992, 38:56-62.
53. Miyachi Y., Niwa Y. Effects of psoriatic sera on the generation of oxygen intermediates by normal polymorphonuclear leucocytes. Arch Dermatol Res 1983, 275:23-26.
54. Kizaki H., Matsuo I., Sakurada T. Xanthine oxidase and guanase activities in normal and psoriatic epidermis. Clin Chim Acta 1977, 75:1-4.
55. Zhang J.C., Savage H.E., Sacks P.G., Delohery T., Alfano R.R., Katz A., et al. Innate cellular fluorescence reflects alterations in cellular proliferation. Lasers Surg Med 1997, 20:319-331.
56. Koivukangas V., Kallionen M., Karvonen J., Autio-Harmainen H., Risteli J., Risteli L., et al. Increased collagen synthesis in psoriasis in vivo. Arch Dermatol Res 1995, 287:171-175.
57. Priestley G.C. Hyperactivity of fibroblasts cultured from psoriatic skin: II. Synthesis of macromolecules. Br J Dermatol 1983, 109:157-164.
58. Priestley G.C., Adams L.W. Hyperactivity of fibroblasts cultured from psoriatic skin: I. Faster proliferation and effect of serum withdrawal. Br J Dermatol 1983, 109:149-156.
59. Dimon-Gadal S., Gerbaud P., Therond P., Guibourdenche J., Anderson W.B., Evain-Brion D., et al. Increased oxidative damage to fibroblasts in skin with and without lesions in psoriasis. J Invest Dermatol 2000, 114:984-989.
60. Stadtman E.R. Protein oxidation and aging. Science 1992, 257:1220-1224.